• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virulence . Novel biomarkers for the prediction of COVID-19 progression a retrospective, multi-center cohort study

tetano

Editor, Senior Moderator
Virulence


. 2020 Dec;11(1):1569-1581.
doi: 10.1080/21505594.2020.1840108.
Novel biomarkers for the prediction of COVID-19 progression a retrospective, multi-center cohort study


Yalan Yu[SUP] 1 [/SUP], Tao Liu[SUP] 2 [/SUP], Liang Shao[SUP] 1 [/SUP], Xinyi Li[SUP] 3 [/SUP], Colin K He[SUP] 4 [/SUP], Muhammad Jamal[SUP] 5 [/SUP], Yi Luo[SUP] 6 [/SUP], Yingying Wang[SUP] 1 [/SUP], Yanan Liu[SUP] 1 [/SUP], Yufeng Shang[SUP] 1 [/SUP], Yunbao Pan[SUP] 6 [/SUP], Xinghuan Wang[SUP] 7 [/SUP], Fuling Zhou[SUP] 1 [/SUP]



Affiliations

Abstract

A pandemic designated as Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading worldwide. Up to date, there is no efficient biomarker for the timely prediction of the disease progression in patients. To analyze the inflammatory profiles of COVID-19 patients and demonstrate their implications for the illness progression of COVID-19. Retrospective analysis of 3,265 confirmed COVID-19 cases hospitalized between 10 January 2020, and 26 March 2020 in three medical centers in Wuhan, China. Patients were diagnosed as COVID-19 and hospitalized in Leishenshan Hospital, Zhongnan Hospital of Wuhan University and The Seventh Hospital of Wuhan, China. Univariable and multivariable logistic regression models were used to determine the possible risk factors for disease progression. Moreover, cutoff values, the sensitivity and specificity of inflammatory parameters for disease progression were determined by MedCalc Version 19.2.0. Age (95%CI, 1.017 to 1.048; P < 0.001), serum amyloid A protein (SAA) (95%CI, 1.216 to 1.396; P < 0.001) and erythrocyte sedimentation rate (ESR) (95%CI, 1.006 to 1.045; P < 0.001) were likely the risk factors for the disease progression. The Area under the curve (AUC) of SAA for the progression of COVID-19 was 0.923, with the best predictive cutoff value of SAA of 12.4 mg/L, with a sensitivity of 83.9% and a specificity of 97.67%. SAA-containing parameters are novel promising ones for predicting disease progression in COVID-19.

Keywords: COVID-19; biomarker; disease progression; predictor; risk factor; serum amyloid A protein.
 
Back
Top Bottom